Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Crucell Terug naar discussie overzicht

De cijfers...

186 Posts
Pagina: «« 1 2 3 4 5 6 ... 10 »» | Laatste | Omlaag ↓
  4. Huppeldepepup 11 augustus 2008 12:31

    • Huppeldepepup

      Lid sinds: 19 feb 2004

      Laatste bezoek: 17 jun 2024

    • Aanbevelingen

      Ontvangen: 1433

      Gegeven: 577

    •    Aantal posts: 4.902

    quote:

    jaja40 schreef:

    En hoppa,de 12 gezien en nu snel op naar de 13.
    Ik ben bang dat de cijfers niet verrassend genoeg zullen zijn voor dat scenario. Hoe dan ook lijkt de 12 uit alle macht te worden vastgehouden. Pas na vrijdag nieuwe kansen.
  6. [verwijderd] 11 augustus 2008 17:21

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Het gaat weer aardig vandaag. Nu maar hopen dat morgen alle verwachtingen compleet verpletterd worden. In positieve zin wel te verstaan. Dan kunnen we misschien nog wel wat verder omhoog.
    Valt het wat tegen, dan kunnen we met z'n allen weer via een piepklein achterdeurtje naar buiten.
    En iedereen weet wat dat voor de koers betekent.
    Maar goed, misschien valt het morgen eens een keer
    heel erg mee. Ben heel benieuwd.

    Grootoorvleermuis.
  7. [verwijderd] 11 augustus 2008 17:45

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Als men morgen de vergelijking maakt met het tweede kwartaal van 2007 dan is dat een leuke headline. Echter, hoe vallen de cijfers uit t.o.v. het eerste kwartaal van dit jaar? Ik duim voor een tweede reversal van de impairement charge van 2006.
    Dan kan mijn dag niet meer stuk.

    Klaar
  8. [verwijderd] 11 augustus 2008 18:49

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    vandaag de handel niet echt kunnen volgen, maar de prof handel was niet gretig met afname calls...ik vermoed dat men na het 'poppetje gezien, kastje dicht' weer meent dat we down kunnen gaan.

    Benieuwd waar de handel het aandeel morgen weer heen ramt. Down as usual, of gaan we eens iets anders zien?

    mvg ivet

    (by the way: hier nog Renovo-volgers? www.renovo.com )
  9. [verwijderd] 11 augustus 2008 19:12

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    yellowfellow schreef:

    ik weet niet wie jij bent, maar ik heb me nog nooit hier vertoond. Misschien iemand anders met dezelfde alias
    Ik hoop het voor je.

    Op de reïncarnatie van Yellow!!! zit hier niemand te wachten.
  12. [verwijderd] 12 augustus 2008 07:54

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    zijn zeer goed ! Omzet 59.6 mln, nettoverlies 7.7 mln en herhaalt de outlook 2008. Analisten verwachtten 51.7 mln resp 12 mln.

    Kostenbesparingen op stoom, voor eind 2009 nog eens 30 mln. Flink up vandaag !
  13. [verwijderd] 12 augustus 2008 07:54

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    12-08-2008 07:48:00 Crucell 'op stoom' met kostenbesparingen
    12-08-2008 07:48:00 Crucell wil EUR30 mln kosten besparen voor eind 2009
    12-08-2008 07:47:00 Crucell; analisten zagen nettoverlies EUR12 mln
    12-08-2008 07:47:00 Crucell; analisten zagen omzet EUR51,7 mln
    12-08-2008 07:47:00 Crucell herhaalt verwachtingen 2008
    12-08-2008 07:47:00 Crucell ziet omzetgroei 20% bij constante valuta in '08
    12-08-2008 07:47:00 Crucell ziet hogere marges, positieve kasstroom in 2008
    12-08-2008 07:46:00 Crucell nettoverlies KW2 2008 EUR7,9 mln
    12-08-2008 07:46:00 Crucell omzet KW2 2008 EUR59,6 mln
  15. [verwijderd] 12 augustus 2008 07:55

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Dirk R. Wijnen schreef:

    12-08-2008 07:48:00 Crucell 'op stoom' met kostenbesparingen
    12-08-2008 07:48:00 Crucell wil EUR30 mln kosten besparen voor eind 2009
    12-08-2008 07:47:00 Crucell; analisten zagen nettoverlies EUR12 mln
    12-08-2008 07:47:00 Crucell; analisten zagen omzet EUR51,7 mln
    12-08-2008 07:47:00 Crucell herhaalt verwachtingen 2008
    12-08-2008 07:47:00 Crucell ziet omzetgroei 20% bij constante valuta in '08
    12-08-2008 07:47:00 Crucell ziet hogere marges, positieve kasstroom in 2008
    12-08-2008 07:46:00 Crucell nettoverlies KW2 2008 EUR7,9 mln
    12-08-2008 07:46:00 Crucell omzet KW2 2008 EUR59,6 mln

    "ziet hogere marges" gaat het hem doen
  18. [verwijderd] 12 augustus 2008 08:04

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Crucell Announces Second Quarter 2008 Results

    Total revenue and other operating income increased by 51% to €59.6 million, compared to €39.4 million in the second quarter of 2007.
    Solid gross margins of 36% and significantly reduced net loss for the second quarter to €7.9 million compared to €18.2 million in Q207.
    2008 full year guidance reiterated: total revenue and other operating income growth of 20% in constant currencies[1]; higher margins; positive cash flow.

    Leiden, The Netherlands (August 12, 2008) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced its financial results for the second quarter of 2008, based on International Financial Reporting Standards (IFRS). These financial results are unaudited.

    Highlights:
    DSM Biologics and Crucell announced another breakthrough in the production of IgG antibodies using Crucell's PER.C6® technology. By employing the PER.C6® human cell line and proprietary XD(TM) technology, a record yield of over 27 grams per liter has been achieved.
    Product sales increased driven by continued growth of paediatric and travel vaccines; in particular Quinvaxem®, Epaxal® and Dukoral®.
    Crucell's rabies monoclonal antibody cocktail entered a second Phase II clinical trial in the Philippines in May 2008. Preliminary results of Crucell's U.S. Phase II study are expected to be presented on October 1 at the 19th annual RITA meeting in Atlanta.
    Crucell announced three non-exclusive STAR® research license agreements; with Bioceros, covering the production of monoclonal antibodies; with Celltrion, Inc. for the manufacturing of biopharmaceuticals and with Toyobo Gene Analysis Co. LTD. for the production of recombinant proteins for third-party customers.
    DSM Biologics and Crucell announced to have entered into an agreement with Avid Bioservices to join their Vendor Network.
    Crucell's operational excellence program "Healthy Ambition" is being rolled out at full steam. Target savings of €30 million by the end of 2009.
    Initial net cost savings of €3 million expected in the second half of 2008.
    Crucell's shareholders appointed Mr. Steve Davis as member of the Supervisory Board at the Annual Meeting for Shareholders, held in May. Dr. Cees de Jong was appointed as a member of the Board of Management for a term of four years.
    Financial Highlights:
    Combined total revenue and other operating income for the quarter of €59.6 million compared to €39.4 in the same quarter of 2007. The increase of 51% (63% in constant currencies) was driven by strong sales of paediatric vaccines, in particular by Quinvaxem®, higher sales of travel vaccines as well as higher license fees.
    Increase of license revenues driven by milestone payments as a result of the start of two phase II clinical studies of Crucell's rabies monoclonal antibody cocktail.
    Gross margins of 36% compared to 39% in the second quarter of 2007 due to a variation in the product mix in this quarter. Gross margins in the second half of 2008 are expected to be positively influenced by the seasonality of our flu product (Inflexal® V) in particular.
    Net loss in the second quarter of 2008 narrowed by 57% to €7.9 million versus a net loss of €18.2 million in the same quarter of 2007.
    Cash and cash equivalents at the end of the second quarter amounted to €106.9 million versus €163.2 million at year-end 2007. Deterioration of cash flow and working capital in the second quarter of 2008 was due to the seasonality of our business, in which we build inventory in the first half of the year to sell our products in the second half of the year. Full year expectations of positive cash flow are reiterated.
    Net cash used in operating activities in the second quarter of 2008 was €18.0 million compared to net cash used in operating activities of €10.2 million in the same quarter of 2007.

    Key Figures Q2 2008:
    (€ million, except net loss per share)
    Second Quarter
    Six months ended June 30
    2008
    2007
    Change
    2008
    2007
    Change

    59.6 39.4 51%
    Total revenues and
    other operating
    income 107.5 74.6 44%
    (7.9) (18.2) (57%)

    Net loss (16.9) (36.7) (54%)
    (0.12) (0.28) Net loss per share
    (basic and diluted) (0.26) (0.57)
    Cash & cash equiv.:
    - June 30, 2008
    - Dec 31, 2007
    106.9
    163.2


  19. [verwijderd] 12 augustus 2008 08:05

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Crucell's Chief Executive Officer Ronald Brus said:

    "In the second quarter of 2008 we saw strong growth of our paediatric vaccines, driven by Quinvaxem®. This innovative, fully-liquid pentavalent vaccine was described by the World Health Organization (WHO) as 'one of the most advanced immunization products available, enabling countries to make a large stride towards their health targets'. We are very proud to have this product in Crucell's paediatric portfolio and expect to see continued growth going forward."

    "Our travel and endemic vaccines, in particular Epaxal® and Dukoral®, also showed solid growth compared to the second quarter of 2007. We will continue to go after untapped markets, amongst others in the U.S., to expand our geographical presence of our travel and endemic vaccines."

    "Together with DSM Biologics we achieved another breakthrough in the production of IgG antibodies using Crucell's PER.C6® technology. A record yield of over 27 grams per liter was achieved, which surpasses all other production systems currently available in the market."

    "We are rolling out our operational excellence program Healthy Ambition at full steam. As an integral part of our growth strategy, Healthy Ambition's goal is to improve overall business performance and reduce costs with 15% by the end of 2009 resulting in an overall run-rate of €30 million savings."

    "In the first half of the year we also started two Phase II clinical studies (in the U.S and in the Philippines) for our Rabies Monoclonal Antibody Cocktail, a collaboration with sanofi pasteur using Crucell's PER.C6® technology. The Rabies Monoclonal Antibody Cocktail is to be used in combination with rabies vaccines for post-exposure prophylaxis against this fatal disease. Preliminary results of our U.S. study are expected to be presented in the U.S. on October 1 at the 19th annual RITA meeting in Atlanta."

    "Based on our second quarter results we reiterate our guidance of combined total revenue and total other operating income for the full year 2008 to grow by 20%[1]. We further expect higher margins and positive cash flow."

    Product and Business Update:

    Product Update
    Product sales for the second quarter of 2008 amounted to €48.4 million and represent sales of paediatric vaccines (56%), travel & endemic vaccines (29%) and other products (15%).

    Paediatric
    In the second quarter of 2008 we saw good growth of our paediatric vaccines, mainly driven by Quinvaxem®.
    Quinvaxem®: Fully liquid pentavalent vaccine against five important childhood diseases.
    Hepavax-Gene®: Recombinant vaccine against hepatitis B.
    Epaxal® Junior: Paediatric dose (0.25mL) of Epaxal® - the only aluminum-free vaccine for children against hepatitis A. The product is currently under registration in selected countries worldwide. Sales in South America have started and European launch is being planned.
    MoRu-Viraten®: Vaccine for protection against measles and rubella (for all age groups).
    Travel and Endemic
    The second quarter of 2008 showed continued growth of our travel and endemic portfolio, where Epaxal® and Dukoral® in particular showed growth compared to the second quarter of 2007. We continue to see significant untapped demand and geographical expansion potential of our travel portfolio.
    Epaxal®: The only aluminium-free vaccine against hepatitis A.
    Vivotif®: The only oral vaccine against typhoid fever.
    Dukoral®: The only oral vaccine against diarrhea caused by cholera and ETEC (enterotoxigenic E.coli).
    Respiratory
    Inflexal® V: A virosomal adjuvanted vaccine against influenza (for all age groups). Due to the seasonality of the product, we build inventory in the first half of the year to sell the respiratory products in the second half of the year.
    Pipeline Update
    Flavimun® - Live Attenuated Yellow Fever Vaccine: Crucell's management expects the registration submission of the Yellow Fever vaccine in Switzerland before the end of 2008.
    Influenza - Seasonal Flu Vaccine (FluCell collaboration with sanofi pasteur): The seasonal influenza vaccine developed by Crucell's partner sanofi pasteur, using PER.C6® technology. Phase II testing of the cell based influenza vaccine was initiated in the U.S. in November 2007. Phase II trials involving healthy adult volunteers in the U.S. focus on the safety profile and immunogenicity of the cell-based vaccine.
    Influenza - H9N2 Pandemic Flu Vaccine: Completed in July 2008. Phase I and II studies were carried out and no serious adverse side effects were reported. In the H9N2 trial Crucell's licensed vaccine method, i.e. a virosomal vaccine was compared to methods less suitable for seasonal vaccine production. As expected the immune response to the unlicensed whole virus vaccine, in particular when adjuvanted with aluminium, appeared to be the most suitable way to induce immunity against a pandemic H9N2 influenza strain and possibly H5N1 strains. Results from this trial showed that subjects who were vaccinated with the virosomal vaccine less frequently reported pain as compared to subjects who were vaccinated with whole virus (with or without adjuvation). We have recently shown (Radosevic et al., Vaccine 2008; 26: 3640-46) that our licensed strategy for seasonal influenza vaccination could also be used for pandemic influenza strains when the immune response was enhanced by additional adjuvants. Within the PanFluVac EU consortium this approach will be tested for a virosomal H5N1 vaccine in humans in 2009.
    Rabies Human Monoclonal Antibody Cocktail: Crucell's rabies monoclonal antibody cocktail, a collaboration with sanofi pasteur using Crucell's PER.C6® manufacturing technology, has entered two Phase II clinical trials (in the US and in the Philippines). The start of these Phase II studies triggered the first milestone payments of a total of up to €66.5 million. This antibody cocktail is to be used in combination with a rabies vaccine for post-exposure prophylaxis against this fatal disease. Based on promising Phase I data in 2007, showing no serious adverse effects and well tolerated treatment, Crucell was granted a Fast Track designation by the FDA Department of Health and Human Services. Crucell will be responsible for the manufacturing of the final product and has retained exclusive distribution rights in Europe, co-exclusive distribution rights in China and the rights to sell to supranational organizations such as UNICEF. Preliminary results of our U.S. study are expected to be presented in the U.S. on October 1 at the 19th annual RITA meeting in Atlanta, at the Centers of Disease Control and Prevention.
    Malaria Vaccine based on AdVac®/PER.C6® Technology: Crucell and its partner, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), are conducting a Phase I trial in the U.S. The study is being carried out on two sites, VanderBilt and Stanford University. The first three cohorts, comprising of 18, 17 and 18 volunteers respectively, have been enrolled. Enrollment for the fourth and final group of volunteers is expected to start soon. Initial findings of this Phase I trial are expected to be available in 2008.
    Tuberculosis Vaccine based on AdVac®/PER.C6® Technology: The development of this vaccine is being carried out in collaboration with the Aeras Global TB Vaccine Foundation. A US Phase I trial (in BCG naïve individuals) has been completed, indicating that the vaccine candidate is
186 Posts
Pagina: «« 1 2 3 4 5 6 ... 10 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.861
AB InBev 2 5.313
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 47.955
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 254
Accsys Technologies 22 9.071
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 169
ADMA Biologics 1 33
Adomos 1 126
AdUX 2 457
Adyen 13 16.930
Aedifica 2 847
Aegon 3.257 320.651
AFC Ajax 537 7.030
Affimed NV 2 5.929
ageas 5.843 109.799
Agfa-Gevaert 13 1.906
Ahold 3.536 74.072
Air France - KLM 1.024 34.435
AIRBUS 1 2
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.792
Alfen 13 17.757
Allfunds Group 3 1.252
Almunda Professionals (vh Novisource) 651 4.248
Alpha Pro Tech 1 17
Alphabet Inc. 1 346
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.781
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.822 240.746
AMG 965 127.445
AMS 3 73
Amsterdam Commodities 303 6.528
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 384
Antonov 22.632 153.605
Aperam 91 14.261
Apollo Alternative Assets 1 17
Apple 5 329
Arcadis 251 8.640
Arcelor Mittal 2.025 318.928
Archos 1 1
Arcona Property Fund 1 273
arGEN-X 15 9.222
Aroundtown SA 1 196
Arrowhead Research 5 9.339
Ascencio 1 22
ASIT biotech 2 697
ASMI 4.107 37.837
ASML 1.762 78.650
ASR Nederland 18 4.199
ATAI Life Sciences 1 7
Atenor Group 1 348
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.877
Axsome Therapeutics 1 177
Azelis Group 1 50
Azerion 7 2.712

Macro & Bedrijfsagenda

  1. 17 juni

    1. Detailhandelsverkopen mei (Chi)
    2. Industriële productie mei (Chi) volitaliteit verwacht
    3. ING Beleggersdag
    4. Flow Traders ex €0,15 dividend
    5. Empire State index juni (VS)

  2. 18 juni

    1. Reserve Bank of Australia rentebesluit 4,35%
    2. ZEW-index economisch sentiment juni (Dld) 50 volitaliteit verwacht
    3. Inflatie mei def. (eur)
    4. Detailhandelsverkopen mei (VS) +0,3%
    5. Industriële productie mei (VS)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda